Graziano Seghezzi
InvestorManaging Partner at Sofinnova Partners
Paris, France
Writes $100K – $5M checks · typically $1.5M
About
Managing Partner at Sofinnova Partners since 2006 and part of the Sofinnova Capital Strategy team, focused on biotech company creation. He has led numerous exits (including Mablink, Corvidia, GlycoVaxyn, and Omthera) and drove the firm's expansion in Italy, founding the BiovelocITA accelerator and the Sofinnova Telethon Fund. He began his VC career at Sofinnova in 2001, worked at Index Ventures (2003-2006), and previously did academic oncology and cardiovascular research at NYU School of Medicine.
Invests in
Biotech
Experience
- Sofinnova PartnersManaging Partnercurrent2017 — present
- Sofinnova PartnersPartner2006 — 2017
- Index VenturesPrincipal2003 — 2006
- Sofinnova PartnersVenture Consultant2002 — 2003Paris, Île-de-France, France
- NYU Langone Medical CenterPostdoc1996 — 2000
Education
- Rotterdam School of Management, Erasmus UniversityMaster of Business Administration (MBA), Entrepreneurship/Entrepreneurial Studies2000 — 2002
- Università di PaviaBiological Sciences, Genetics and Microbiology
Skills & more
Languages English · French · Italian
From Graziano's professional profile.
Same school
Also attended Rotterdam School of Management, Erasmus University140
+ 134 more
Shared employers
Also worked at Sofinnova Partners44
+ 38 more
Also worked at Index Ventures125
+ 119 more
Also worked at NYU Langone Medical Center19
+ 13 more
Deals · 2
Hookipa PharmaBoard seat
via Sofinnova Partners · filed Feb 2019
CORVIDIA THERAPEUTICS, INC.Board seat
via Sofinnova Partners · filed May 2018 · $60M raise
Attribution from SEC filings, press coverage, and firm rosters.




































